2022
DOI: 10.1111/jdv.18356
|View full text |Cite
|
Sign up to set email alerts
|

Dupilumab improves both histaminergic and touch‐evoked itch sensitization (hyperknesis) in atopic dermatitis: a pilot study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 6 publications
(8 citation statements)
references
References 11 publications
0
4
0
Order By: Relevance
“…Although we did not investigate other factors that could be involved in hyperknesis (e.g. dysfunction of neural circuits in the spine 12 and immune status 13 ) and did not evaluate alloknesis in the cases, this case series suggests that hyperknesis does occur in PHI and seems to be associated with reduced IENFs.…”
Section: Discussionmentioning
confidence: 93%
“…Although we did not investigate other factors that could be involved in hyperknesis (e.g. dysfunction of neural circuits in the spine 12 and immune status 13 ) and did not evaluate alloknesis in the cases, this case series suggests that hyperknesis does occur in PHI and seems to be associated with reduced IENFs.…”
Section: Discussionmentioning
confidence: 93%
“…The monoclonal antibody Dupilumab targets the alpha-subunit of the IL-4 receptor, reducing type 2 cytokines IL-4 and IL-13. A recent small-scale study found Dupilumab to not only reduce itch, but also reduce histaminergic and mechanical hyperknesis in AD patients ( Hashimoto et al, 2022 ). The anti-IL-31 receptor alpha monoclonal antibody, Nemolizumab, may reduce IL-31 induced sensory nerve stimulation, thereby reducing peripheral sensitization ( Ständer et al, 2022 ).…”
Section: Treatments For Neural Sensitization Of Itchmentioning
confidence: 99%
“…One study showed that dupilumab resulted in a significant improvement in the baseline itch in patients with AD, while the control group which was treated with topical cortical steroids alone experienced increased histaminergic and mechanical hyperknesis. 22 Another report on dupilumab for the treatment of pruritus of unknown origin also demonstrates that the anti-pruritic effects of dupilumab are not simply a sequelae of the reduction in inflammation. 23…”
Section: Il-4 and Il-13 Blockade Has A Direct Effect On The Neurologi...mentioning
confidence: 99%